BPAMU
LGND icon

BTG Pactual Asset Management US’s Ligand Pharmaceuticals LGND Stock Holding History

BTG Pactual Asset Management US’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Buy
1,123
+74
+7% +$17.4K 0.02% 317
2026
Q1 		$209K Buy
+1,049
New +$208K 0.02% 300

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BTG Pactual Asset Management US's LGND Position: Q2 2026 in Review

BTG Pactual Asset Management US increased its Ligand Pharmaceuticals (LGND) stake by 7.1% in Q2 2026, buying an estimated $17.4K and bringing the position to 1,123 shares worth $355K. The position accounts for 0.02% of the portfolio, ranked #317.

BTG Pactual Asset Management US first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • BTG Pactual Asset Management US held 1,123 shares of Ligand Pharmaceuticals worth $355K as of Q2 2026.
  • BTG Pactual Asset Management US bought 74 Ligand Pharmaceuticals shares in Q2 2026, an estimated $17.4K.
  • Ligand Pharmaceuticals made up 0.02% of BTG Pactual Asset Management US's portfolio in Q2 2026, its #317 holding.
  • BTG Pactual Asset Management US first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on BTG Pactual Asset Management US's 13F filing for Q2 2026, filed 14 Aug 2026.